Evidence map›Paper›PMID 32762772›Full record

ArticleActa neuropathologica communications2020

Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicity.

Oeystein R Brekk, Joanna A Korecka, Cecile C Crapart, Mylene Huebecker, Zachary K MacBain, Sara Ann Rosenthal, Miguel Sena-Esteves, David A Priestman, Frances M Platt, Ole Isacson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Rare-Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  2. Article
  3. Sphingolipidoses: expanding the spectrum of α-synucleinopathies.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. CorticalProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Advances in Optical Sensors ofBioconjugate chemistry · 2022
    Review
  10. Review
  11. Review
  12. Insights into Lewy body disease from rare neurometabolic disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Oeystein R BrekkNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA.
Joanna A KoreckaNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA.
Cecile C CrapartNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA.
Mylene HuebeckerDepartment of Pharmacology, University of Oxford, Oxford, UK.
Zachary K MacBainNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA.
Sara Ann RosenthalNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA.
Miguel Sena-EstevesDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.
David A PriestmanDepartment of Pharmacology, University of Oxford, Oxford, UK.
Frances M PlattDepartment of Pharmacology, University of Oxford, Oxford, UK.
Ole IsacsonNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA. isacson@hms.harvard.edu.
Penelope J HallettNeuroregeneration Institute, McLean Hospital / Harvard Medical School, Belmont, MA, USA. phallett@mclean.harvard.edu.ORCID 0000-0002-8858-9096
Harvard University · USUniversity of Oxford · GBBrigham and Women's Hospital · USUniversity of Bonn · DEUniversity of Massachusetts Chan Medical School · US

Funding

Prevention of complement and immune-mediated Lewy body dementiaR01AG060195 · NIA · MCLEAN HOSPITAL · PI HALLETT, PENELOPE JANE, HASTINGS, MICHELLE L · 2018 to 2022
$2.9M
Critical analysis of glycosphingolipid pathways in aging and Parkinsons diseaseR01NS092667 · NINDS · MCLEAN HOSPITAL · PI HALLETT, PENELOPE JANE · 2015 to 2018
$1.2M
NIA NIH HHS R01 AG060195NIA NIH HHS R01AG060195NINDS NIH HHS 1R01NS092667NINDS NIH HHS R01 NS092667Wellcome Trust 202834/Z/16/Z
6 · The paper itself

Abstract

Sandhoff disease (SD) is a lysosomal storage disease, caused by loss of β-hexosaminidase (HEX) activity resulting in the accumulation of ganglioside GM2. There are shared features between SD and Parkinson's disease (PD). α-synuclein (aSYN) inclusions, the diagnostic hallmark sign of PD, are frequently found in the brain in SD patients and HEX knockout mice, and HEX activity is reduced in the substantia nigra in PD. In this study, we biochemically demonstrate that HEX deficiency in mice causes formation of high-molecular weight (HMW) aSYN and ubiquitin in the brain. As expected from HEX enzymatic function requirements, overexpression in vivo of HEXA and B combined, but not either of the subunits expressed alone, increased HEX activity as evidenced by histochemical assays. Biochemically, such HEX gene expression resulted in increased conversion of GM2 to its breakdown product GM3. In a neurodegenerative model of overexpression of aSYN in rats, increasing HEX activity by AAV6 gene transfer in the substantia nigra reduced aSYN embedding in lipid compartments and rescued dopaminergic neurons from degeneration. Overall, these data are consistent with a paradigm shift where lipid abnormalities are central to or preceding protein changes typically associated with PD.

Indexed as

alpha-SynucleinAnimalsbeta-N-AcetylhexosaminidasesDopaminergic NeuronsFemaleGangliosidesLipidsMaleMiceMice, Inbred C57BLParkinson DiseaseRatsRats, Sprague-DawleySandhoff DiseaseUp-Regulationalpha-Synucleinbeta-N-AcetylhexosaminidasesGangliosidesLipidsLipid bindingNeuroprotectionParkinson’s diseaseSandhoff diseaseα-Synucleinβ-Hexosaminidase

Identifiers

PMID32762772
PMCPMC7409708
OpenAlexW3047035888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.